• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 01-Jul-2022 EOD, Market Closed
SENSEX
52,907.93
-111.01 (-0.21%)
NIFTY
15,752.05
-28.20 (-0.18%)
    No Companies Visited

Back to news list
  • Dr. Reddy's biotech arm inks exclusive agreement with Olema Oncology

    Dr. Reddy's Laboratories said that Olema Pharmaceuticals Inc. and Aurigene Discovery Technologies have entered into an exclusive global license agreement to discover and develop novel cancer therapies.



    The two companies have joined hand to research, develop and commercialize novel small molecule inhibitors of an undisclosed oncology target.

    Aurigene Discovery Technologies is a clinical stage biotech company committed to bringing novel therapeutics for the treatment of cancer and inflammation and a wholly owned subsidiary of Dr. Reddy's Laboratories.

    San Francisco-based Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers.

    Under the terms of the agreement, Olema will make an upfront licensing payment of $8 million for rights to a pre-existing Aurigene program. Aurigene will be eligible for up to $60 million in potential clinical development and regulatory milestones and up to $370 million in potential commercial milestones, as well as royalties ranging from the mid-single digits to the low double digits based on annual net sales.

    During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts. Olema and Aurigene will jointly direct further preclinical work and, if successful, Olema will lead clinical development as well as regulatory and commercial activities.

    Murali Ramachandra, Ph.D., chief executive officer of Aurigene, said: "This agreement with Olema further validates Aurigene's proven expertise in discovery and preclinical development of effective cancer therapeutics. We look forward to the continued development of an Aurigene program, which will now be ably supported by the extensive development capability of Olema."

    Dr. Reddy's Laboratories is an integrated pharmaceutical company. It offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

    The drug maker's consolidated net profit tumbled 76% to Rs 87.50 crore in 15% increase in revenues to Rs 5436.80 crore in Q4 March 2021 over Q4 December 2021.

    Shares of Dr. Reddy's Laboratories advanced 3% to end at Rs 4326.10 on the BSE yesterday.

    Back to news list
Previous Stories :
More
Hot Pursuit News

Quick Links

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
9769005430
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 01-Jul-2022
  •  ( 14:34) Nifty hovers at 15,650; Sensex drops 454 pts  
  •  ( 13:34) Barometers further pare losses  
  •  ( 13:11) Eicher Motors sells 6,307 CV units In June'22  
  •  ( 13:04) Ashok Leyland total sales soars 125% YoY in June  
  •  ( 12:37) Sensex drops 408 pts, RIL tumbles over 6%  
  •  ( 12:31) Atul Auto rises as June 2022 total sales jumps 151% YoY  
  •  ( 12:22) Tilaknagar Inds inks service agreement with Globus Spirits  
  •  ( 11:56) REC board recommends 1:3 bonus issue  
  •  ( 11:42) Nifty hovers over 15,600; breadth negative  
  •  ( 10:43) Bajaj Auto reports muted sales in June  
  •  ( 10:35) Nifty below 15,600; breadth remains positive  
  •  ( 10:20) Lupin gets US FDA nod for schizophrenia treatment drug  
  •  ( 09:48) Escorts Kubota tractor sales slide 20% YoY in June  
  •  ( 09:35) Hindustan Copper board OKs fund raising proposals  
  •  ( 09:35) Indices decline in early trade on negative global cues  
  •  ( 09:25) Market breadth was postive  
  •  ( 08:51) IRB Infra SPV gets completion certificate for UP road project  
  •  ( 08:31) Asian stocks trading lower  
Show News
01 July 2022 00:00
2772.95
(2.80 %)
645.15
(1.33 %)
5614.80
(3.97 %)
11326.35
(3.63 %)
673.40
(-1.54 %)
4384.35
(-0.35 %)
2210.65
(2.18 %)
976.35
(0.34 %)
1353.65
(0.46 %)
2282.80
(2.34 %)
704.00
(-0.40 %)
807.50
(1.63 %)
1478.05
(1.15 %)
284.35
(3.99 %)
1669.95
(0.55 %)
1569.55
(0.80 %)
1108.40
(1.22 %)
8396.60
(-0.87 %)
17789.20
(1.69 %)
140.55
(-1.82 %)
206.50
(-2.53 %)
2408.95
(-7.14 %)
466.90
(0.24 %)
826.70
(-0.49 %)
873.30
(0.73 %)
3316.15
(1.56 %)
1010.60
(1.09 %)
1946.10
(0.19 %)
5693.60
(1.67 %)
421.80
(1.38 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.